RNAi: antifungal therapy against Invasive pulmonary aspergillosis (IPA) in humans

---

Review Article

Author Details : Maneesh Kumar*, Roshan Kamal Topno, Ratnesh Kumar

Volume : 10, Issue : 3, Year : 2023

Article Page : 123-128

https://doi.org/10.18231/j.ijmr.2023.022

Suggest article by email

Get Permission

---

Abstract

Noncoding RNAs, known as miRNAs, regulate gene expression. Most miRNAs are converted from DNA sequences into primary miRNAs, processed into precursors, and matured. Survival or virulence of Aspergillus species is targeted by RNAi antifungal treatment. Silencing these genes can reduce fungal proliferation and pathogenicity, thereby improving therapy. RNAi can be used to treat Aspergillus; however, most research has been conducted in controlled laboratory or animal studies. The immune system
neutralizes Aspergillus spores, so not everyone gets sick. Aspergillosis can range from moderate allergic reactions to invasive, life-threatening disease. MiRNAs have been studied in numerous diseases, but their role in immune responses to pulmonary and systemic fungal infections is still being discovered. During disease progression, fungal pathogens can alter signaling and expression of miRNAs in the genetic network. Future investigations on the biological purpose of miRNAs, previously assumed to be a consequence of miRNA synthesis, will illuminate the regulatory function of the miRNA network in plant innate immunity. MiRNAs and their intended targets present opportunities for novel pathogen-fighting strategies and technologies.

Keywords: miRNAs, Aspergillus Aspergillosis, Immune reactions, Antifungal therapy.

How to cite : Kumar M, Topno R K, Kumar R, RNAi: antifungal therapy against Invasive pulmonary aspergillosis (IPA) in humans. Indian J Microbiol Res 2023;10(3):123-128

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.